Tag
NASDAQ: CMPS
Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial
Theo Marchetti · Sep 23, 2026
Definium Therapeutics reports 5.1‑point gap in second Phase 3 anxiety study
Theo Marchetti · Sep 23, 2026